

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

- BRAJLDTAM:** Low Dose Adjuvant Tamoxifen for Resected Ductal Carcinoma In Situ
- BRAVENH:** Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
- GIAVDURPG, GIAVDUR4:** Durvalumab with Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
- GITREMDUR:** Tremelimumab and Durvalumab for Advanced Hepatocellular Carcinoma
- LUAVLOR:** Lorlatinib for ALK-Positive Advanced Non-Small Cell Lung Cancer

Cancer Drug Manual®

New: Teclistamab **Revised:** Durvalumab, Filgrastim, Tamoxifen; Chemotherapy and Stability Chart: Filgrastim, Irinotecan

Drug Update

Buserelin delisted from Benefit List

Benefit Drug List

New: BRAJLDTAM, GIAVDUR4, GIAVDURPG, GITREMDUR, LUAVLOR

NEW Protocols, PPOs and Patient Handouts

BR BRAJLDTAM, GIAVDUR4, GIAVDURPG, GITREMDUR, GUBAVE, LUAVLOR

REVISED Protocols, PPOs and Patient Handouts

BR BRAJLHRHAI, BRAJLHRHT, BRAJTAM, BRAJTTW, BRAVENH, BRAVLHRHAI, BRAVLHRHT, BRAVPALAI, BRAVPBFLV, BRAVRIBAI, BRAVSG | **CN** CNAJ12TZRT, CNAJZRT, BRAVRBFLV, CNBEV, CNMODPCV, CNTEM60, CNTEMOZ | **GI** GIATZB, GIAVPG, UGICABO, GILEN, GIREGO, GISORAF, UGIPRRT | **GO** GOOVCAJ | **GU** GUMCSPABI, GUMCSPAPA, GUMCSPENZ, UGUNMPDAR, UGUNMPENZ, UGUPABI, UGUPAJABI, UGUPAPA, GUPDOC, GUPDOCADT, UGUPENZ, GUPLHRH | **HN** HNLADC | **LK** LKMDSA | **LU** LUAVALE, LUAVBRI, LUAVCER, LUAVCRIZF | **LY** LYABVD, LYAVDBV, LYBRENTUX, LYBV, LYDARCBDF, LYDARCBDF | **MO** MODEXA | **SM** SMAJDT, SMAJNIV, SMAJNIV4, SMAJPEM, SMAJPEM6, SMAVALIPNI, SMAVCEM, SMAVCET, SMAVDAB, SMAVDT, SMAVEB, SMAVFIPI, SMAVI, SMAVIPI, SMAVIPNI, SMAVNIV, SMAVNIV4, SMAVPEM, SMAVPEM6, USMAVTEB, SMAVTMZ, SMAVTRA, SMAVVC, SMAVVEM

Correction

April Issue: Editor's Choice Announcement for Darolutamide and DOCetaxel for Metastatic Castration Sensitive Prostate Cancer

Resources and Contact Information

Editor's Choice

New Programs

Effective 1 May 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Breast

Low Dose Adjuvant Tamoxifen for Resected Ductal Carcinoma In Situ (BRAJLDTAM) — The BC Cancer Breast Tumour Group is introducing adjuvant treatment with low-dose tamoxifen (10 mg every other day) for patients with fully resected hormone receptor-positive ductal carcinoma in situ (DCIS). In a multicenter phase III study, low-dose tamoxifen 5 mg daily resulted in less neoplastic events (invasive

New Programs

breast cancer or DCIS) compared to placebo. Safety results indicated that drug-related serious adverse events were not increased with low-dose tamoxifen compared to similar trials using standard-dose tamoxifen 20 mg. Although there was a slight increase in daily hot flashes with tamoxifen compared to placebo, adherence was similar in both arms.[1]

Trastuzumab Deruxtecan (ENHERTU) for Metastatic HER-2 Low Breast Cancer (BRAVENH) – The BC Cancer Breast Tumour Group is expanding the trastuzumab deruxtecan (ENHERTU) protocol from patients with HER2-positive breast cancer to include patients with HER2-low breast cancer, regardless of hormone receptor status. HER2-low is defined as immunohistochemistry (IHC) 1+, or IHC 2+ with negative FISH test. It comprises about 60% of HER2-negative metastatic breast cancer.

In the phase III DESTINY-Breast04 trial compared to physician's choice of chemotherapy, trastuzumab deruxtecan (ENHERTU) was associated with improved overall survival, progression-free survival, and objective response rate. Trastuzumab deruxtecan was associated with manageable toxicities consistent with the known safety profile.[2]

Gastrointestinal

Durvalumab with Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer (GIAVDURPG, GIAVDUR4) – The BC Cancer Gastrointestinal Tumour Group is introducing durvalumab with gemcitabine and cisplatin as first-line treatment of locally advanced unresectable or metastatic biliary tract cancer. In the phase III, randomized, double-blinded TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin demonstrated a statistically significant improvement in overall survival compared to placebo plus gemcitabine and cisplatin. Durvalumab (plus gemcitabine and cisplatin) showed an improvement in progression-free survival and was associated with a manageable toxicity profile with no additional safety concerns and no detriment to health-related quality of life.[3]

Tremelimumab and Durvalumab for Advanced Hepatocellular Carcinoma (GITREMDUR) – The BC Cancer Gastrointestinal Tumour Group is introducing tremelimumab, a new CTLA-4 checkpoint inhibitor, and durvalumab as first-line treatment of advanced hepatocellular carcinoma in patients with previously untreated unresectable or metastatic hepatocellular carcinoma. Patients must be classified as Child-Pugh score class A liver function and not be eligible for curative or locoregional therapies. In the phase III, randomized, open-label, sponsor-blinded, multicentre, global HIMALAYA trial, tremelimumab plus durvalumab demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to sorafenib. Tremelimumab plus durvalumab was associated with manageable toxicities consistent with the known safety profile of other immuno-oncology checkpoint inhibitors.[4]

Lung

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer with Lorlatinib (LUAVLOR) – The BC Cancer Lung Tumour Group is introducing lorlatinib as first-line treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer. In the phase III CROWN trial comparing to crizotinib, lorlatinib has shown to improve progression-free survival and overall response rate, with the overall survival data still immature. Although lorlatinib was generally associated with a higher incidence of adverse events than crizotinib, this did not result in a higher rate of dose modification or interruption

Editor's Choice

New Programs

and treatment discontinuation, or a significant difference in health-related quality of life. The most common adverse events were hyperlipidemia, edema, increased weight, peripheral neuropathy, and cognitive effects.[5]

1. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. *J Clin Oncol* 2019; 37(19):1629-1637.
2. CADTH Reimbursement Recommendations. Trastuzumab Deruxtecan (Enhertu). July 2023.
3. CADTH Reimbursement Recommendations. Durvalumab (Imfinzi). February 2023.
4. CADTH Reimbursement Recommendations. Tremelimumab (Imjudo) in Combination with Durvalumab (Imfinzi). November 2023.
5. CADTH Reimbursement Recommendations. Lorlatinib (Lorbrena). April 2022.

Cancer Drug Manual[®]

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

The **Teclistamab Interim Monograph** has been expanded and a **Patient Handout** has been developed. The following sections have been added or expanded: *Pharmacokinetics, Special Precautions, Side Effects, Interactions, and Dosage Guidelines*. Expert review was provided by Dr. Christopher Venner (medical oncologist, BC Cancer Myeloma Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). **Teclistamab** is a bispecific T-cell engager that targets B cell maturation antigen (BMCA) expressed on multiple myeloma cells and CD3 receptors expressed on T cells. Teclistamab is used in the treatment of multiple myeloma. Dosing follows a step-up dosing regimen for the first cycle, with dose increments given on days 1, 3, and 5. The usual dose for cycle 2 onwards is 1.5 mg/kg given once weekly in a 4-weekly cycle.

Highlights from these documents include:

- cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been reported with teclistamab; refer to BC Cancer SCCRS and SCICANS protocols
- premedication with corticosteroid, antihistamine, and antipyretic is recommended prior to all step-up doses and first full treatment dose to reduce the risk of CRS
- antimicrobial/antiviral prophylaxis may be required to prevent reactivation of infections such as herpes zoster and Hepatitis B

Revised Documents

Durvalumab Monograph

Uses: added liver cancer

Cautions: added information related to timing of treatment

Dosage Guidelines: added new BC Cancer protocols GIAVDUR4, GIAVDURPG, GITREMDUR

Filgrastim Monograph, Patient Handout, and Chemotherapy Preparation and Stability Chart

Common Trade names: added new biosimilar formulations

Cancer Drug Manual[®]

Cautions: updated *Pregnancy* section; deleted FDA Pregnancy Category

Supply and Storage: added new biosimilars and updated references

Solution Preparation and Compatibility: updated references

Parenteral Administration table: updated content per current template style

Patient Handout: updated Banner to include brand names for the new biosimilars; updated template language throughout

Chemotherapy Preparation and Stability Chart: added Pfizer brand (NIVESTYM[®])

Irinotecan Chemotherapy Preparation and Stability Chart

Added Eugia brand

Tamoxifen Monograph

Special Precautions: updated *Cautions, Carcinogenicity, Fertility, Pregnancy, Breastfeeding, and Special Populations*

Side Effects: updated link to Breast Cancer Management Guidelines in *Hot flashes* paragraph

Interactions: updated link to Breast Cancer Management Guidelines

Supply and Storage: updated for current Canadian brands

Dosage Guidelines: added dosing and references for BC Cancer low-dose protocol BRAJLDTAM

CDM Editorial Board Changes

The Cancer Drug Manual[®] Editorial Review Board would like to announce that **Michelle LaFreniere**, Nurse Educator (Oncology), Provincial Practice Nursing (BC Cancer – Victoria) is stepping away from the board for a temporary position associated with CST cutover. Good luck with your new responsibilities Michelle. **Raman Sandhu**, Clinical Nurse Educator (BC Cancer – Vancouver) will be replacing Michelle on the during her absence. Welcome Raman!

Drug Update

Buserelin delisted from Benefit List

Buserelin is a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of patients with prostate cancer and breast cancer. **Starting 1 May 2024**, buserelin will be **removed** from the BC Cancer Benefit Drug List. Therefore, please do not start any new patients on buserelin.

Other LHRH agonists (goserelin, leuprolide) with equivalent efficacy and toxicity are available on the Benefit Drug List. We strongly recommend selecting an alternate LHRH agonist for your existing patients. If a switch to an alternate LHRH agonist is not appropriate, please submit a request to the BC Cancer Compassionate Access Program (CAP) for buserelin to ensure continuity of care.

Benefit Drug List

New Programs

Effective 01 May 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Adjuvant Treatment of Resected Ductal Carcinoma in Situ using Tamoxifen	BRAJLDTAM	Class I
Treatment of Advanced Biliary Tract Cancer using Durvalumab	GIAVDUR4	Class I
First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	GIAVDURPG	Class I
First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab	GITREMDUR	Class I
Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Lorlatinib	LUAVLOR	Class I

Revised Programs

Effective 01 May 2024, buserelin has been deleted from the following treatment programs on the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	Class I
Palliative Therapy for Breast Cancer using a LHRH agonist and Tamoxifen	BRAJLHRHT	Class I
Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist	BRAVPALAI	Class I
Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant With or Without LHRH Agonist	BRAVPBFLV	Class I
Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor With or Without LHRH Agonist	BRAVRIBAI	Class I
First-Line Treatment of Castration Sensitive, Metastatic Prostate Cancer Using DOCEtaxel and Androgen Deprivation Therapy	GUPDOCADT	Class I
Therapy for Prostate Cancer using LHRH Agonist (Goserelin or Leuprolide)	GUPLHRH	Class I

Benefit Drug List

New Filgrastim Biosimilar

Effective 01 May 2024, **filgrastim biosimilar NYPOZI** has been added for the existing indications for filgrastim on the BC Cancer [Benefit Drug List](#).

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol Title	Protocol	PPPO	Handout
BRAJLDTAM	Adjuvant Treatment of Resected Ductal Carcinoma in Situ using Tamoxifen	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
GIAVDUR4	Treatment of Advanced Biliary Tract Cancer using Durvalumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GIAVDURPG	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GITREMDUR	First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GUBAVE	Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
LUAVLOR	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Lorlatinib	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJLHRHAI	Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–
BRAJLHRHT	Palliative Therapy for Breast Cancer using a LHRH agonist and Tamoxifen	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–
BRAJTAM	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen	<i>Physician name, eligibility, treatment, precautions, and references updated. Caution added</i>	–	–
BRAJTTW	Adjuvant Therapy for Breast Cancer using Weekly PAclitaxel and Trastuzumab	–	–	<i>Protocol code and side effect table update, laboratory testing clarification</i>
BRAVENH	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	<i>Eligibility, exclusions, and references updated. Tests clarified</i>	–	–
BRAVLHRHAI	Therapy for Advanced Breast Cancer using a LHRH Agonist and an Aromatase Inhibitor	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–
BRAVLHRHT	Palliative Therapy for Breast Cancer using a LHRH agonist and Tamoxifen	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–
BRAVPALAI	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed, tests updated</i>	–
BRAVPBFLV	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant With or Without LHRH Agonist	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed, tests updated</i>	–
BRAVRBFLV	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant With or Without LHRH Agonist	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–
BRAVRIBAI	Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Treatment updated – buserelin removed</i>	<i>Treatment updated – buserelin removed</i>	–

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BRAVSG	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Eligibility updated</i>	--	--
CN Neuro-Oncology				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Title updated, Eligibility clarified</i>	--	<i>Title corrected</i>
CNAJTZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Eligibility clarified, Caution deleted</i>	--	--
CNBEV	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine	<i>Eligibility clarified, Tests clarified, treatment updated, dose modifications updated)</i>	<i>Pre-chemo metrics updated, removed flushing comments, labs updated</i>	--
CNMODPCV	Modified PCV Chemotherapy Of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vinCRISStine	<i>Eligibility clarified</i>	--	--
CNTEM60	Therapy for Newly Diagnosed Malignant Brain Tumours with MGMT Methylation in Elderly Patients using Temozolomide	<i>Eligibility clarified, Caution deleted</i>	--	--
CNTEMOZ	Therapy for Malignant Brain Tumours Using Temozolomide	<i>Eligibility clarified</i>	--	--
GI Gastrointestinal				
GIATZB	First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab	<i>Eligibility updated</i>	--	--
GIAVPG	First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum	<i>Eligibility, cautions, tests updated, treatment duration clarified</i>	<i>Tests updated</i>	--
UGICABO	Treatment of Advanced Hepatocellular Carcinoma using Cabozantinib	<i>Eligibility updated</i>	--	--
GILEN	Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	<i>Eligibility updated</i>	--	--
GIREGO	Treatment of Advanced Hepatocellular Carcinoma Using Regorafenib	<i>Eligibility updated</i>	--	--
GISORAF	Therapy for Advanced Hepatocellular Carcinoma using SORafenib	<i>Eligibility updated</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
UGIPRRT	Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Neuroendocrine Tumours	<i>Title, eligibility, exclusions, treatment, dose modifications, precautions, references updated. Tests clarified</i>	<i>Pre-chemo metrics updated, tests clarified</i>	–
GO Gynecologic				
GOOVCAG	Treatment of Advanced Ovarian Cancer in Patients Who Have Progressed or Recurred Following Firstline Platinum-based Treatment Using CARBOplatin and Gemcitabine	–	<i>Optional Day 14 lab removed</i>	–
GU Genitourinary				
GUMCSPABI	Therapy for Metastatic Castration Sensitive Prostate Cancer using Abiraterone and predniSONE	<i>Eligibility and tests updated, dexamethasone 0.75 mg changed to 0.5 mg</i>	<i>Dexamethasone 0.75 mg changed to 0.5 mg, tests updated</i>	–
GUMCSPAPA	Treatment of Metastatic Castration Sensitive Prostate Cancer using Apalutamide	<i>Eligibility and tests updated</i>	<i>Reminder and tests updated</i>	–
GUMCSPENZ	Treatment for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	–
UGUNMPDAR	Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Darolutamide	<i>Eligibility and tests updated</i>	<i>Reminder and tests updated</i>	–
UGUNMPENZ	Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	<i>Eligibility, exclusions, and tests updated</i>	<i>Tests updated</i>	–
UGUPABI	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and predniSONE	<i>Tests updated, dexamethasone 0.75 mg option changed to 0.5 mg</i>	<i>Dexamethasone 0.75 mg changed to 0.5 mg, tests updated</i>	–
UGUPAJABI	Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	<i>Tests Updated</i>	–	–
UGUPAPA	Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide	<i>Eligibility, exclusions, and tests updated</i>	<i>Reminder and tests updated</i>	–
GUPDOC	Palliative Therapy for Metastatic Hormone Refractory Prostate Cancer Using DOCEtaxel and predniSONE	–	<i>Hypersensitivity banner added</i>	–
GUPDOCADT	First-Line Treatment of Castration Sensitive, Metastatic Prostate Cancer Using DOCEtaxel and Androgen Deprivation Therapy	<i>Treatment updated – buserelin removed, tests updated</i>	<i>Hypersensitivity banner added</i>	–

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
UGUPENZ	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	–
GUPLHRH	Therapy for Prostate Cancer using LHRH Agonist (Goserelin or Leuprolide)	<i>Title updated, treatment updated – buserelin removed</i>	<i>Treatment updated - buserelin removed</i>	–
HN Head & Neck				
HNLADCF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel, CISplatin and Infusional Fluorouracil	–	<i>Hypersensitivity banner added</i>	–
LK Leukemia				
LKMDSA	Therapy of Myelodysplastic Syndrome and Acute Myeloid Leukemia using azaCITIDine	<i>Note added, exclusions updated</i>	–	–
LU Lung				
LUVALE	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib	<i>Eligibility updated, exclusions added</i>	–	–
LUAVBRI	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib	<i>Eligibility updated, exclusions added</i>	–	–
LUAVCER	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Ceritinib	<i>Eligibility, exclusions and link in footer updated</i>	–	–
LUAVCRIZF	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	<i>Eligibility and exclusions updated</i>	–	–
LY Lymphoma				
LYABVD	Treatment of Hodgkin Lymphoma with DOXOrubicin, Bleomycin, vinBLASTine, and Dacarbazine	<i>Tests, supportive medications, precautions updated</i>	<i>pre-chemo metrics, tests updated</i>	–
LYAVDBV	Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with DOXOrubicin, vinBLASTine, Dacarbazine and Brentuximab Vedotin	<i>Tests, supportive meds, dose modifications, precautions updated</i>	<i>pre-chemo metrics, tests updated</i>	–
LYBRENTUX	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin	<i>Tests, supportive medications updated</i>	<i>Tests updated</i>	–
LYBV	Consolidation Therapy Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma Using Brentuximab Vedotin	<i>Tests, supportive medications, precautions updated</i>	<i>Tests updated</i>	–

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LYDARCBDF	Treatment of Previously Untreated Light Chain Amyloidosis and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	–
MO Miscellaneous Origin				
MODEXA	Dexamethasone as Treatment for Cerebral Edema or CNS Swelling	–	<i>dexamethasone 0.75 mg tablet option removed</i>	–
SM Skin & Melanoma				
SMAJDT	Adjuvant Treatment of Stage III and IV, BRAF mutated, fully resected Melanoma Using daBRAFeinib and Trametinib	<i>Physician contact phone number updated</i>	–	–
SMAJNIV	Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Nivolumab	<i>Tests, physician contact phone number updated</i>	–	–
SMAJNIV4	Adjuvant Treatment of Resected Stage III - IV NED Melanoma Using 4-Weekly Nivolumab	<i>Physician contact phone number updated</i>	–	–
SMAJPEM	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab	<i>Physician contact phone number updated</i>	–	–
SMAJPEM6	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab	<i>Physician contact phone number updated</i>	–	–
SMAVALIPNI	Treatment of Unresectable or Metastatic Melanoma using Alternative Dosing Regimen of Ipilimumab and Nivolumab	<i>Physician contact phone number updated</i>	–	–
SMAVCEM	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cemiplimab	<i>Physician contact phone number updated</i>	–	–
SMAVCET	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cetuximab	<i>Tests, physician contact phone number updated</i>	–	–
SMAVDAB	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib	<i>Physician contact phone number updated</i>	–	–
SMAVDT	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib and Trametinib	<i>Physician contact phone number updated, minor formatting</i>	–	–

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
SMAVEB	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib	<i>Physician contact phone number updated</i>	--	--
SMAVFIPI	First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab	<i>Physician contact phone number updated</i>	--	--
SMAVI	Treatment of Advanced C-Kit Positive Melanoma Using iMAtinib	<i>Tests, physician contact phone number updated</i>	--	--
SMAVIPI	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab	<i>Physician contact phone number updated</i>	--	--
SMAVIPNI	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab	<i>Tests, physician contact phone number updated</i>	--	--
SMAVNIV	Treatment of Unresectable or Metastatic Melanoma Using Nivolumab	<i>Tests, physician contact phone number updated</i>	--	--
SMAVNIV4	Treatment of Unresectable or Metastatic Melanoma Using 4-Weekly Nivolumab	<i>Tests, physician contact phone number updated</i>	--	--
SMAVPEM	Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab	<i>Tests, physician contact phone number updated</i>	--	--
SMAVPEM6	Treatment of Unresectable or Metastatic Melanoma Using 6-Weekly Pembrolizumab	<i>Physician contact phone number updated</i>	--	--
USMAVTEB	Treatment of Metastatic Uveal Melanoma using Tebentafusp	<i>Treatment duration clarified</i>	--	--
SMAVTMZ	Palliative Therapy for Malignant Melanoma with Brain Metastases using Temozolomide	<i>Physician contact phone number updated</i>	--	--
SMAVTRA	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib	<i>Physician contact phone number updated</i>	--	--
SMAVVC	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and Cobimetinib	<i>Physician contact phone number updated</i>	--	--
SMAVVEM	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using vemURAFenib	<i>Physician contact phone number updated</i>	--	--

Correction

April Issue

Editor's Choice Announcement for for Darolutamide and DOCetaxel for Metastatic Castration Sensitive Prostate Cancer should read the overall survival as "not reached vs. 48.9 months", not "e (43.7 months vs. 42.4 months".

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
Alison Pow, BScPharm